Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:FPRX
- CUSIP: N/A
- Web: www.fiveprime.com
Capitalization:- Market Cap: $859.26 million
- Outstanding Shares: 27,897,000
Average Prices:- 50 Day Moving Avg: $29.96
- 200 Day Moving Avg: $36.84
- 52 Week Range: $26.65 - $60.98
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.01
- P/E Growth: 0.10
Sales & Book Value:- Annual Revenue: $34.31 million
- Price / Sales: 24.27
- Book Value: $12.80 per share
- Price / Book: 2.33
Profitability:- EBIDTA: ($111,050,000.00)
- Net Margins: -250.98%
- Return on Equity: -21.81%
- Return on Assets: -18.92%
Debt:- Current Ratio: 10.98%
- Quick Ratio: 10.98%
Misc:- Average Volume: 292,148 shs.
- Beta: 4.23
- Short Ratio: 7
Frequently Asked Questions for Five Prime Therapeutics (NASDAQ:FPRX)
What is Five Prime Therapeutics' stock symbol?
Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."
How were Five Prime Therapeutics' earnings last quarter?
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) announced its quarterly earnings data on Thursday, May, 4th. The company reported ($1.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.96) by $0.25. The firm earned $10.13 million during the quarter, compared to the consensus estimate of $6.05 million. Five Prime Therapeutics had a negative return on equity of 21.81% and a negative net margin of 250.98%. The firm's revenue for the quarter was up 55.8% on a year-over-year basis. During the same period in the previous year, the business earned ($0.49) EPS. View Five Prime Therapeutics' Earnings History.
Where is Five Prime Therapeutics' stock going? Where will Five Prime Therapeutics' stock price be in 2017?
7 brokers have issued 12 month target prices for Five Prime Therapeutics' shares. Their predictions range from $54.00 to $94.00. On average, they expect Five Prime Therapeutics' stock price to reach $65.20 in the next year. View Analyst Ratings for Five Prime Therapeutics.
What are analysts saying about Five Prime Therapeutics stock?
Here are some recent quotes from research analysts about Five Prime Therapeutics stock:
- 1. Jefferies Group LLC analysts commented, "Near-term focus is on initial Ph2 data for cabiralizumab in PVNS at ASCO. Roche’s emactuzumab in PVNS showed an ~80% RR at high dose, but resulting in 2 cases of lupus per FPRX." (5/5/2017)
- 2. According to Zacks Investment Research, "Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California. " (5/2/2017)
- 3. Cowen and Company analysts commented, "We believe Five Prime has amongst the leading IO drug discovery platforms in the industry. The BMS partnership provides validation. Multiple clinical readouts in 2017 provide catalysts to drive value generation. Lead asset Cabira has significant potential in solid tumors, we expect FPA144 to succeed in FGFR2b+ gastric cancer (2019), and we see high POS for Cabira in PVNS. Initiating at Outperform." (3/24/2017)
- 4. Instinet analysts commented, "We are initiating on Five Prime Therapeutics (FPRX) with a Buy rating and a $94, 12-month target price. We recommend owning FPRX shares ahead of potentially transformational mid-2017 readouts. We anticipate 2017 data from cabiralizumab and key competitors will further de-risk cabiralizumab's anti-CSF1R mechanism in immuno-oncology, define pivotal clinical paths, establish initial market opportunities, and differentiate its safety versus competitors." (3/1/2017)
Who are some of Five Prime Therapeutics' key competitors?
Some companies that are related to Five Prime Therapeutics include NovoCure Limited (NVCR), Array BioPharma (ARRY), Dermira (DERM), Acceleron Pharma (XLRN), Amarin Corporation PLC (AMRN), Xencor (XNCR), Clinigen Group PLC (CLIN), Insmed (INSM), Forward Pharma A/S (FWP), Omeros Corporation (OMER), Acorda Therapeutics (ACOR), Aduro Biotech (ADRO), Synergy Pharmaceuticals (SGYP), Ascendis Pharma A/S (ASND), Achaogen (AKAO), PTC Therapeutics (PTCT), NeuroDerm (NDRM) and ZIOPHARM Oncology (ZIOP).
Who are Five Prime Therapeutics' key executives?
Five Prime Therapeutics' management team includes the folowing people:
- Lewis T. Williams M.D. Ph.D., Chairman of the Board, President, Chief Executive Officer
- Marc L. Belsky, Chief Financial Officer, Senior Vice President
- Aron Marc Knickerbocker MBA, Chief Operating Officer, Director
- Kevin Baker Ph.D., Senior Vice President, Development Sciences
- Helen Louise Collins M.D., Senior Vice President and Chief Medical Officer
- Francis Willard Sarena J.D., Chief Strategy Officer and Secretary
- Mark D. McDade, Lead Independent Director
- Garry Nicholson, Director
- Franklin M. Berger, Independent Director
- Fred E. Cohen Ph.D. M.D., Independent Director
Who owns Five Prime Therapeutics stock?
Five Prime Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Rockefeller Financial Services Inc. (0.02%), Creative Planning (0.02%) and Daiwa SB Investments Ltd. (0.02%). Company insiders that own Five Prime Therapeutics stock include Adage Capital Partners Gp Llc, Francis Willard Sarena, Franklin M Berger, Lewis T Williams, Marc Belsky, Peder Jensen and William R Ringo. View Institutional Ownership Trends for Five Prime Therapeutics.
Who sold Five Prime Therapeutics stock? Who is selling Five Prime Therapeutics stock?
Five Prime Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Daiwa SB Investments Ltd.. Company insiders that have sold Five Prime Therapeutics stock in the last year include Francis Willard Sarena, Lewis T Williams, Peder Jensen and William R Ringo. View Insider Buying and Selling for Five Prime Therapeutics.
Who bought Five Prime Therapeutics stock? Who is buying Five Prime Therapeutics stock?
How do I buy Five Prime Therapeutics stock?
Shares of Five Prime Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Five Prime Therapeutics' stock price today?
One share of Five Prime Therapeutics stock can currently be purchased for approximately $29.85.
MarketBeat Community Rating for Five Prime Therapeutics (NASDAQ FPRX)MarketBeat's community ratings are surveys of what our community members think about Five Prime Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Five Prime Therapeutics (NASDAQ:FPRX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 7 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $65.20 (118.43% upside) |
Analysts' Ratings History for Five Prime Therapeutics (NASDAQ:FPRX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/8/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $55.00 | Medium |  |
| 3/24/2017 | Cowen and Company | Initiated Coverage | Outperform | | High | |
| 3/1/2017 | Instinet | Initiated Coverage | Buy -> Buy | $94.00 | N/A | |
| 3/1/2017 | Nomura | Initiated Coverage | Buy | | N/A | |
| 11/7/2016 | Credit Suisse Group | Reiterated Rating | Buy | $54.00 | N/A | |
| 10/25/2016 | Citigroup Inc. | Initiated Coverage | Buy | $65.00 | N/A | |
| 8/8/2016 | Leerink Swann | Reiterated Rating | Outperform | $45.00 -> $58.00 | N/A | |
| 5/19/2016 | Oppenheimer Holdings, Inc. | Reiterated Rating | Outperform | $48.00 | N/A | |
| 4/12/2016 | BMO Capital Markets | Initiated Coverage | Market Perform | $50.00 | N/A | |
| 12/4/2015 | Wells Fargo & Company | Reiterated Rating | Outperform | | N/A | |
(Data available from 7/24/2015 forward)
Earnings History for Five Prime Therapeutics (NASDAQ:FPRX)Earnings History by Quarter for Five Prime Therapeutics (NASDAQ FPRX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/4/2017 | Q1 2017 | ($0.96) | ($1.21) | $6.05 million | $10.13 million | View | Listen | |
| 2/23/2017 | Q4 2016 | ($0.57) | ($0.73) | $7.09 million | $8.30 million | View | N/A | |
| 11/3/2016 | Q3 | ($0.51) | ($0.72) | $7.50 million | $6.70 million | View | N/A | |
| 8/4/2016 | Q2 | ($0.56) | ($0.49) | $6.38 million | $9.23 million | View | N/A | |
| 5/5/2016 | Q1 | ($0.71) | ($0.49) | $5.26 million | $6.50 million | View | N/A | |
| 3/10/2016 | Q4 | $9.67 | $10.63 | $354.16 million | $363.34 million | View | Listen | |
| 11/4/2015 | Q315 | ($0.99) | ($0.93) | $4.90 million | $5.90 million | View | N/A | |
| 8/6/2015 | Q215 | ($0.44) | ($0.45) | $6.92 million | $6.30 million | View | N/A | |
| 5/13/2015 | Q1 | ($0.46) | ($0.44) | $4.77 million | $4.30 million | View | Listen | |
| 3/17/2015 | Q414 | ($0.40) | ($0.55) | $5.39 million | $4.65 million | View | N/A | |
| 11/10/2014 | Q3 2014 | ($0.40) | ($0.33) | $5.22 million | $6.06 million | View | N/A | |
| 8/5/2014 | Q2 14 | ($0.27) | ($0.46) | $5.39 million | $4.98 million | View | N/A | |
| 3/25/2014 | Q4 | ($0.40) | ($0.43) | $1.52 million | $3.79 million | View | Listen | |
| 11/12/2013 | | ($0.57) | ($2.74) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Five Prime Therapeutics (NASDAQ:FPRX)2017 EPS Consensus Estimate: ($4.21)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.97) | ($0.97) | ($0.97) |
| Q2 2017 | 1 | ($1.03) | ($1.03) | ($1.03) |
| Q3 2017 | 1 | ($1.08) | ($1.08) | ($1.08) |
| Q4 2017 | 1 | ($1.13) | ($1.13) | ($1.13) |
(Data provided by Zacks Investment Research)
Dividend History for Five Prime Therapeutics (NASDAQ:FPRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Five Prime Therapeutics (NASDAQ:FPRX)Insider Ownership Percentage: 6.50%
Institutional Ownership Percentage: 85.95%
Insider Trades by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/1/2017 | William R Ringo | Director | Sell | 500 | $46.73 | $23,365.00 | |
| 2/1/2017 | William R Ringo | Director | Sell | 500 | $46.17 | $23,085.00 | |
| 1/18/2017 | Francis Willard Sarena | Insider | Sell | 3,636 | $47.39 | $172,310.04 | |
| 1/3/2017 | William R Ringo | Director | Sell | 500 | $51.07 | $25,535.00 | |
| 12/23/2016 | Lewis T Williams | CEO | Sell | 30,000 | $50.50 | $1,515,000.00 | |
| 12/1/2016 | William R Ringo | Director | Sell | 500 | $57.72 | $28,860.00 | |
| 11/28/2016 | Francis Willard Sarena | Insider | Sell | 1,710 | $60.14 | $102,839.40 | |
| 11/25/2016 | Francis Willard Sarena | Insider | Sell | 34,654 | $60.38 | $2,092,408.52 | |
| 11/9/2016 | Peder Jensen | Director | Sell | 8,130 | $55.30 | $449,589.00 | |
| 11/1/2016 | William R Ringo | Director | Sell | 500 | $48.67 | $24,335.00 | |
| 10/3/2016 | William R Ringo | Director | Sell | 500 | $52.00 | $26,000.00 | |
| 9/1/2016 | William R Ringo | Director | Sell | 500 | $44.20 | $22,100.00 | |
| 8/1/2016 | William R Ringo | Director | Sell | 500 | $50.77 | $25,385.00 | |
| 7/27/2016 | Peder Jensen | Director | Sell | 12,195 | $49.50 | $603,652.50 | |
| 4/22/2016 | Franklin M Berger | Director | Buy | 5,000 | $49.47 | $247,350.00 | |
| 4/22/2016 | Marc Belsky | CFO | Sell | 34,102 | $50.00 | $1,705,100.00 | |
| 4/21/2016 | Lewis T Williams | CEO | Sell | 48,671 | $48.05 | $2,338,641.55 | |
| 4/19/2016 | Franklin M Berger | Director | Buy | 6,090 | $47.06 | $286,595.40 | |
| 4/15/2016 | Lewis T Williams | CEO | Sell | 1,405 | $48.00 | $67,440.00 | |
| 4/14/2016 | Lewis T Williams | CEO | Sell | 2,725 | $48.00 | $130,800.00 | |
| 4/6/2016 | Lewis T Williams | CEO | Sell | 52,801 | $43.09 | $2,275,195.09 | |
| 4/6/2016 | Marc Belsky | CFO | Sell | 20,814 | $45.04 | $937,462.56 | |
| 3/30/2016 | Francis Willard Sarena | EVP | Sell | 10,000 | $40.01 | $400,100.00 | |
| 3/30/2016 | Lewis T Williams | CEO | Sell | 23,259 | $40.02 | $930,825.18 | |
| 3/30/2016 | Marc Belsky | CFO | Sell | 13,876 | $40.01 | $555,178.76 | |
| 3/2/2016 | Lewis T Williams | CEO | Sell | 23,259 | $36.01 | $837,556.59 | |
| 2/4/2016 | Lewis T. Williams | CEO | Sell | 71,229 | $33.35 | $2,375,487.15 | |
| 1/27/2016 | Francis Willard Sarena | EVP | Sell | 30,000 | $35.22 | $1,056,600.00 | |
| 10/15/2015 | Adage Capital Partners Gp Llc | Major Shareholder | Sell | 125,000 | $27.75 | $3,468,750.00 | |
| 10/15/2015 | Lewis T. Williams | CEO | Sell | 72,352 | $27.24 | $1,970,868.48 | |
| 9/21/2015 | Lewis T Williams | CEO | Sell | 2,648 | $22.06 | $58,414.88 | |
| 6/22/2015 | Lewis T Williams | CEO | Sell | 75,000 | $24.67 | $1,850,250.00 | |
| 1/28/2015 | Franklin M Berger | Director | Buy | 25,000 | $27.03 | $675,750.00 | |
| 1/15/2015 | Franklin M Berger | Director | Buy | 10,049 | $26.17 | $262,982.33 | |
| 11/28/2014 | Franklin M Berger | Director | Buy | 1,951 | $21.04 | $41,049.04 | |
| 11/4/2014 | Lewis T Williams | CEO | Sell | 32,603 | $13.08 | $426,447.24 | |
| 10/30/2014 | Lewis T Williams | CEO | Sell | 17,397 | $13.13 | $228,422.61 | |
| 9/23/2013 | Brian G Atwood | Director | Buy | 76,923 | $13.00 | $999,999.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Five Prime Therapeutics (NASDAQ:FPRX)
Latest Headlines for Five Prime Therapeutics (NASDAQ:FPRX)
| Source: |
|
| Date | Headline |
|---|
 | Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety ...
www.nasdaq.com - July 18 at 12:42 AM |
 | Five Prime Therapeutics, Inc. (FPRX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 17 at 8:52 PM |
 | Five Prime Therapeutics (FPRX) Commences Patient Dosing in Phase 1 Clinical Safety Trial Evaluating FPA144 in ... - StreetInsider.com
www.streetinsider.com - July 17 at 7:41 PM |
 | Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety Trial Evaluating FPA144 in Gastric Cancer in Japan in Preparation for Future Global Late-Stage Development
finance.yahoo.com - July 17 at 7:41 PM |
| Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Expected to Announce Quarterly Sales of $10.15 Million
www.americanbankingnews.com - July 16 at 8:28 AM |
| Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Expected to Announce Earnings of -$1.18 Per Share
www.americanbankingnews.com - July 14 at 2:50 PM |
| Five Prime Therapeutics, Inc. – Value Analysis (NASDAQ:FPRX) : July 4, 2017
finance.yahoo.com - July 5 at 7:06 AM |
| Five Prime Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : FPRX-US : July 3, 2017
finance.yahoo.com - July 3 at 6:30 PM |
 | Five Prime Therapeutics founder, CEO to step down - MarketWatch
www.marketwatch.com - June 22 at 5:59 PM |
| Five Prime Therapeutics, Inc. (FPRX) Expected to Post Quarterly Sales of $10.15 Million
www.americanbankingnews.com - June 22 at 11:12 AM |
| Five Prime's Williams Plans To Transition From CEO To Executive Chairman In 2018
www.nasdaq.com - June 22 at 9:41 AM |
| Five Prime Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : FPRX-US : June 22, 2017
finance.yahoo.com - June 22 at 9:41 AM |
 | Five Prime chief Williams to transition to Executive Chairman; shares ease 1% after hours
seekingalpha.com - June 21 at 6:53 PM |
| Five Prime Therapeutics Announces Lewis T. “Rusty” Williams Plans to Transition from CEO to Executive Chairman of the Board in 2018
finance.yahoo.com - June 21 at 6:53 PM |
| Five Prime Therapeutics founder, CEO to step down
finance.yahoo.com - June 21 at 6:53 PM |
| Five Prime Therapeutics, Inc. (FPRX) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - June 20 at 7:02 PM |
| -$1.18 EPS Expected for Five Prime Therapeutics, Inc. (FPRX) This Quarter
www.americanbankingnews.com - June 20 at 12:30 PM |
| Jefferies Group LLC Reaffirms "Buy" Rating for Five Prime Therapeutics Inc (FPRX)
www.americanbankingnews.com - June 8 at 10:26 PM |
| Five Prime Therapeutics (FPRX) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 8 at 6:18 PM |
 | Five Prime Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference
feeds.benzinga.com - June 5 at 7:01 PM |
| Five Prime Therapeutics updates on FPA144 results - Seeking Alpha
seekingalpha.com - June 5 at 5:22 PM |
| Five Prime Therapeutics (FPRX) Reports Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in ... - StreetInsider.com
www.streetinsider.com - June 5 at 11:06 AM |
| Five Prime Therapeutics (FPRX) Announces Updated Data From Phase 1 Trial of Single-Agent FPA144 at ASCO ... - StreetInsider.com
www.streetinsider.com - June 5 at 11:06 AM |
| Five Prime Therapeutics Inc (FPRX) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - June 4 at 4:20 PM |
| Five Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 ...
www.nasdaq.com - June 4 at 11:18 AM |
| Five Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis (PVNS) at 2017 ASCO Annual Meeting
finance.yahoo.com - June 4 at 11:18 AM |
| Five Prime Therapeutics updates on FPA144 results
seekingalpha.com - June 3 at 4:37 PM |
 | Five Prime Therapeutics Presents Updated Data From Phase 1 Trial of Single-Agent FPA144 at 2017 ASCO Annual ... - GlobeNewswire (press release)
globenewswire.com - June 3 at 9:30 AM |
| Five Prime Therapeutics Presents Updated Data From Phase 1 Trial of Single-Agent FPA144 at 2017 ASCO Annual Meeting
finance.yahoo.com - June 3 at 9:30 AM |
| Five Prime Therapeutics Inc (FPRX) Expected to Post Quarterly Sales of $10.15 Million
www.americanbankingnews.com - May 27 at 9:24 AM |
| Five Prime Therapeutics Inc (FPRX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 26 at 6:47 PM |
| Analysts Expect Five Prime Therapeutics Inc (FPRX) Will Post Earnings of -$1.18 Per Share
www.americanbankingnews.com - May 25 at 8:08 AM |
| ETFs with exposure to Five Prime Therapeutics, Inc. : May 23, 2017
finance.yahoo.com - May 23 at 4:56 PM |
| Five Prime Therapeutics Inc (FPRX) Short Interest Update
www.americanbankingnews.com - May 21 at 11:14 AM |
| Five Prime Therapeutics (FPRX) ASCO abstract published on phase I/II dose escalation and expansion study of cabiralizumab
www.streetinsider.com - May 18 at 10:06 AM |
| Five Prime Therapeutics (FPRX) Names Garry Nicholson to Board of Directors - StreetInsider.com
www.streetinsider.com - May 17 at 5:17 PM |
| Five Prime Welcomes Garry Nicholson to Board of Directors
finance.yahoo.com - May 15 at 4:56 PM |
| Five Prime Therapeutics At An Attractive Entry Level
seekingalpha.com - May 12 at 10:51 PM |
| ETFs with exposure to Five Prime Therapeutics, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 5:55 PM |
| Five Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
finance.yahoo.com - May 9 at 5:09 PM |
| Jefferies Group Comments on Five Prime Therapeutics Inc's FY2021 Earnings (FPRX)
www.americanbankingnews.com - May 8 at 12:30 PM |
| Five Prime Announces First Quarter 2017 Results and Provides ... - GlobeNewswire (press release)
globenewswire.com - May 5 at 10:29 PM |
| Five Prime Therapeutics posts 1Q loss
finance.yahoo.com - May 5 at 5:28 PM |
| Jefferies Group LLC Reaffirms Buy Rating for Five Prime Therapeutics Inc (FPRX)
www.americanbankingnews.com - May 5 at 11:58 AM |
| Five Prime Therapeutics' (FPRX) CEO Rusty Williams on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 5 at 3:29 AM |
| Five Prime Therapeutics Inc (FPRX) Releases Quarterly Earnings Results, Misses Estimates By $0.25 EPS
www.americanbankingnews.com - May 5 at 12:08 AM |
| Five Prime Announces First Quarter 2017 Results and Provides Business Update
finance.yahoo.com - May 4 at 5:27 PM |
| Investor Network: Five Prime Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 4 at 12:19 PM |
| Five Prime Therapeutics (FPRX) Receives Coverage Optimism Score of 0.33
www.americanbankingnews.com - May 3 at 8:52 PM |
| Five Prime Therapeutics Inc (FPRX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 3 at 1:11 AM |
Five Prime Therapeutics (FPRX) Chart for Monday, July, 24, 2017
